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Dilated Cardiomyopathy (DCM) is a leading cause of sudden cardiac death characterized
by impaired pump function and dilatation of cardiac ventricles. In this review we
discuss various in silico approaches to elucidating the mechanisms of genetic mutations
leading to DCM. The approaches covered in this review focus on bridging the spatial
and temporal gaps that exist between molecular and cellular processes. Mutations in
sarcomeric regulatory thin filament proteins such as the troponin complex (cTn) and
Tropomyosin (Tm) have been associated with DCM. Despite the experimentally-observed
myofilament measures of contractility in the case of these mutations, the mechanisms
by which the underlying molecular changes and protein interactions scale up to organ
failure by these mutations remains elusive. The review highlights multi-scale modeling
approaches and their applicability to study the effects of sarcomeric gene mutations
in-silico. We discuss some of the insights that can be gained from computational models
of cardiac biomechanics when scaling from molecular states to cellular level.
Keywords: dilated cardiomyopathy, troponin, Tropomyosin, cross-bridge, myofilament, modeling, mechanics,
Markov
INTRODUCTION
Dilated Cardiomyopathy (DCM) is one of the four classified forms of cardiomyopathy besides
hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrythmogenic
right ventricular dysplasia/cardiomyopathy (ARVD/C) (Richardson et al., 1996; Seidman and
Seidman, 2001). DCM, one of the major causes of cardiac death, is characterized by impaired
systolic function and dilatation of one or both ventricles (Richardson et al., 1996; Kärkkäinen
and Peuhkurinen, 2007). Hemodynamically, contractility is depressed and Pressure-Volume (PV)
loops are right-shifted in DCM. In 30–50% of cases DCM is linked to familial etiology, including
mutations in the regulatory thick and thin myofilament proteins - myosin, actin, the Troponin
(Tn) complex, Tropomyosin (Tm), and Titin (Ttn) (Kärkkäinen and Peuhkurinen, 2007; Lu et al.,
2013). Many times DCM presents with conduction defects and sequelae of other cardiac defects.
This is more common with cytoskeletal and z-disc mutations (Seidman and Seidman, 2001; Chang
and Potter, 2005). Genome Wide Association Studies (GWAS) have helped identify many of the
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sarcomeric mutations associated with the phenotype of DCM
(Kamisago et al., 2000; Li et al., 2001; Olson et al., 2001;Mogensen
et al., 2004; Murphy et al., 2004; Lakdawala et al., 2010, 2012a;
Branishte et al., 2013; Pérez-Serra et al., 2016). Despite the
identification of sarcomeric mutations associated with DCM,
it is still difficult to predict the exact functional consequences
of the mutation at the cellular level based on its molecular
structure and function. Identified sarcomeric mutations may
represent a gain of function or loss of function at the cellular level,
as assessed by myofilament mechanics (Kamisago et al., 2000;
Spudich and Rock, 2002; McNally et al., 2013). Furthermore, a
spatial and temporal translation of the cellular level mechanical
phenotype to an organ level DCM phenotype has not been
seamlessly achieved. These patho-physiological translative events
from genetic to molecular to cellular to organ level, underscore
the need for investigation at and across all biological scales to fully
comprehend the development of DCM (Spudich, 2014).
Previous experimental studies, incorporating structural data
from x-ray crystallography and nuclear magnetic resonance
(NMR) into molecular dynamic (MD) models and in-vitro
molecular assays, have reported changes in molecular properties
of various DCM associated sarcomeric mutants. Findings
include altered calcium binding affinity (Robinson et al., 2007;
Kekenes-Huskey et al., 2012), rate of cTnC hydrophobic patch
opening (Dewan et al., 2016), acto-myosin affinity (Moore
et al., 2012), altered surface charge distribution on coiled-coil
region of Tm (Olson et al., 2001), Titin to z-disc protein T-
cap/Telethonin affinity (Thirumal Kumar et al., 2016) and cTnC-
cTnI interactions (Mogensen et al., 2004; Dewan et al., 2016).
The impact of molecular alteration to cellular phenotype can
be qualitatively or semi-quantitatively intuitive in some cases.
For example a decrease in calcium binding affinity of cTnC will
lead to decreased thin filament activation and force development.
However, the exact quantification of such an effect is still to be
reported for various mutants and unanswered questions remain.
Will a 25% decrease in calcium binding affinity of cTnC lead
to a 50% decrease in thin filament activation which would
result in 50% decrease in maximal force response or will it
trigger compensatory molecular mechanisms and result in a 10%
decrease in thin filament activation and force generation? Or
does a 10% decrease in thin filament activation imply a 20%
decrease in calcium binding affinity of cTnC? As an example, a
recent study reported that the severity of DCM is determined
by the ratio of mutant to wildtype TnnT2 gene transcript in
1K210 cTnT transgenic mice, as absence of one allele of TnnT2
does not lead to a protein deficit (Ahmad et al., 2008). The
quantitative translation of molecular perturbation to cellular
events and vice versa warrants more studies. Nonetheless, it has
been reported that identified genetic mutations in contractile
active force-generating sarcomeric proteins (excluding Titin)
exhibit a very specific DCM phenotype without any other
associated cardiac phenotype such as hypertrophy or conduction
defects with a high prevalence in young people (Mogensen
et al., 2004; Memo et al., 2013). This would suggest that diverse
molecular abnormalities converge at the cellular phenotype,
which then trigger the cardiac remodeling leading to DCM.
Indeed depressed contractile function is a common cellular
phenotype in DCM despite variable molecular mechanisms
(Mirza et al., 2005).
Experimental studies, using the skinned muscle preparation
or intact cardiomyocytes from gene-targeted mouse models
(Du et al., 2007), adenoviral-mediated transfection (Morimoto
et al., 2002; Lu et al., 2003; Mirza et al., 2005; Lim et al.,
2008), in-vitro protein exchange experiments (Dweck et al., 2010)
for in-vitro protein motility assays (Mirza et al., 2005; Memo
et al., 2013), mammalian two-hybrid luciferase assay system
(Mogensen et al., 2004; Murphy et al., 2004), steady-state force-
calcium assays (Morimoto et al., 2002; Lu et al., 2003), and
contractility assays (Biesiadecki et al., 2007; Lim et al., 2008;
Dweck et al., 2010), have reported alterations in key mechanical
properties of myofilaments in DCM. These include changes in
calcium sensitivity (Robinson et al., 2002; Mirza et al., 2005;
Du et al., 2007; Lim et al., 2008; Dweck et al., 2010; Memo
et al., 2013; Kalyva et al., 2014), thick and thin myofilament
cooperativity and cross-bridge (XB) cycling rates (Moore et al.,
2012), as a functional outcome of many identified sarcomeric
DCM mutations. Most studies have reported a decrease in
calcium sensitivity of myofilaments as a consistent functional
phenotype for DCM identified sarcomere mutations (Murphy
et al., 2004; Mirza et al., 2005; Du et al., 2007; Robinson et al.,
2007; Memo et al., 2013). Interestingly, I61Q cTnC mutant in
mice (neither found nor associated with DCM clinically), that
has decreased calciummyofilament binding affinity, recapitulates
DCM phenotype cellularly and in vivo (Davis et al., 2016).
However, exceptions to this have been reported wherein both
an increase and no change in calcium sensitivity were reported
in DCM (Dweck et al., 2008; Memo et al., 2013). Dweck et
al. reported that there is a decrease in calcium sensitivity of
tension development in G159D cTnC mutant only when it
is incorporated in regulated actomyosin filaments and not in
isolated cTnC (Dweck et al., 2008), highlighting the effect of
protein interactions as the hierarchy of structural organization
becomes more physiological and complex in the contractile
apparatus. Furthermore, Memo et al. reported a decrease in
calcium sensitivity of myofilaments for four DCM associated
mutants (K36Q TnI, R141W TnT, 1K210 TnT, E40K Tm), no
change in calcium sensitivity of one mutant (E54K Tm) and
increase in calcium sensitivity in another (D230N Tm) (Memo
et al., 2013). These observations suggest that decreased calcium
sensitivity is a dominant stimulus sufficient to cause DCM, but
is neither necessary, nor the only cellular mechanism triggering
the remodeling observed in DCM. A recent study postulated
that the blunting of the relationship between calcium sensitivity
of myofilaments and PKA mediated beta-adrenergic stimulation
via cTnI phosphorylation (Memo et al., 2013) in sarcomeric
DCM mutants might be the defining cellular phenotype for
DCM regardless of the directional shift in calcium sensitivity. It
should be noted that aside from DCM mutations in contractile
sarcomere proteins that lead to diminished force production,
mutations in other key cytoskeletal and sarcomere proteins
like the z-disc proteins and Titin can lead to disruptions
in transmission of force, sensing of force and mechano-
transduction which are also causative toward DCM (Chang
and Potter, 2005). These observations suggest that molecular
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interactions and effects of various DCM mutants converge to
a depressed contractile phenotype at the cellular level due to
alterations in (a) calcium sensitivity of myofilaments, (b) thin-
filament activation, (c) maximal ATPase activity, (d) in-vitro
motility (e) calcium affinity of Tn and (f) mechano-transduction,
thereby triggering the signaling mechanism leading to DCM
(Chang and Potter, 2005; Lakdawala et al., 2012b). Further
studies are warranted to establish the key converging cellular
mechanism/s and signaling pathway/s in DCM.
It is interesting to note that both HCM and DCM can be
caused by different mutations within the same contractile protein
gene. HCM is a more common familial disease with a contrasting
phenotype of hypertrophied ventricle and preserved systolic
function. These observations imply that there are either two
different signaling pathways distinguishing these phenotypes or
a graded response within the same pathway. An earlier study
in transgenic mice with a truncation allele of Myosin Binding
protein C (MyBP-C), known to cause HCM in man, exhibited a
graded response such that heterozygotes resulted in HCM and
homozygotes in DCM (McConnell et al., 1999). In contrast,
Ahmad et al. and Ramratnam et al. reported that the ratio of
mutated to wildtype transcript of TnT is critical in determining
severity of DCM and not haploinsufficiency (Ahmad et al.,
2008; Ramratnam et al., 2016). Nonetheless, given that most
studies report a contrasting cellular phenotype to HCM with
directionally opposite shifts in calcium sensitivity, two separate
pathway theory is strongly supported. This is corroborated
by a recent study where the authors propose that modeling
the tension integral of cardiomyocytes can help distinguish
between DCM and HCM (Davis et al., 2016). Notably, a recent
RNAseq study profiling molecular signaling in DCM and HCM
reported that profibrotic and metabolic networks can distinguish
between the two phenotypes (Burke et al., 2016). Multi-scale
studies quantifying genotype to functional cellular phenotype
will help address these theories. The convergence of various
molecular defects to fewer cellular phenotypes to a singular DCM
phenotype via cardiac remodeling is notable.
Clinically, mutations are prevalent from birth in familial
DCM. However, the temporal transition to DCM is not yet
understood (Tardiff, 2012). A recent study using tissue Doppler
and strain echocardiography, showed that even early on there
are subtle indications (Lakdawala et al., 2012b). In subclinical
DCM mutation carriers, reduced systolic myocardial velocity,
strain and strain-rate were reported despite normal LV geometry,
ejection fraction and diastolic function (Lakdawala et al., 2012b).
Early diagnosis in such cases can provide with much needed
time (Lakdawala et al., 2012b). It is also important to note that
some HCM patients develop dilated ventricles at later stages for
example in patients with mutations E180V in Tm and R92W in
cTnT (Chang and Potter, 2005). Studies have shown this to be
distinct from DCM phenotype (Ohba et al., 2007). So in familial
DCM at the whole heart level there is subtle manifestation of
DCM from birth and transition to late stage DCM eventually.
Mechanical and pathway driven changes lead to this cardiac
remodeling (Burke et al., 2016; Davis et al., 2016). Investigations
on the effects of DCMmutations quantitatively and qualitatively,
in animal model studies, linking genotype to muscle phenotype
i.e., from molecular level changes to myofilament level changes
to intact tissue level changes to whole heart level changes are
scarce (Ahmad et al., 2008; Ramratnam et al., 2016). This is due
to the technical challenges and expense of carrying out such an
expansive study to experimentally measure data on a single DCM
mutation. Additionally, as studies report cellular data, isolating
the singular effect of the genetic mutation becomes difficult due
to downstream effects of the mutation that also contribute to the
systemic perturbations leading to the phenotype.
A potential way to study the mechanical effects of genetic
mutations comprehensively is by multi-scale computational
modeling. Cardiac muscle biomechanics has been experimentally
and computationally investigated in molecular machineries of
sarcomeric protein complexes (Varguhese and Li, 2011; Lindert
et al., 2012b, 2015), in thick and thin myofilaments (Rice and
de Tombe, 2004; Campbell et al., 2010; Dewan et al., 2016),
in isolated cardiomyocytes under steady-state and dynamic
conditions (Hussan et al., 2006; Rice et al., 2008), in myocardium,
and in the whole heart (Göktepe et al., 2010; Campbell and
McCulloch, 2011; Trayanova, 2011; Kerckhoffs et al., 2012; Zhang
et al., 2016). An integrative mathematical formulation to scale
from protein level changes to the cardiomyocyte function is yet
to be implemented. Parameterization of computational models
requires collating data from various studies for a single mutation
at various spatial and temporal scales. This results in data from
variable experimental conditions and requires standardization in
terms of (a) temperature, (b) species, and (c) bridging of spatial
and temporal scales, in order to input model parameters (Tøndel
et al., 2015; Dewan et al., 2016). In this review we discuss various
in silico approaches and the challenges thereof, by examining
previously identified and experimentally studiedDCMmutations
in thin filament proteins Tn and Tm, with the goal of elucidating
the mechanical effects of sarcomeric mutations from molecular
level to the cellular scales.
CARDIAC MUSCLE CONTRACTION AND
EFFECTS OF DCM MUTANTS IN
REGULATORY THIN FILAMENT PROTEINS
cTn AND TM
Cardiac muscle contraction is triggered following calcium
induced calcium release (CICR) from the sarcoplasmic reticulum
(SR) (Fabiato, 1983). In 1954, two groundbreaking studies
proposed the sliding filament theory of muscle contraction
describing themolecular basis of muscle contraction (Huxley and
Niedergerke, 1954; Huxley and Hanson, 1954). According to the
sliding filament theory, thin (actin) and thick (myosin) filaments
slide past each other, while maintaining absolute lengths, during
contraction to generate contractile force. Cardiac TnC (cTnC),
a 18 kDa thin filament protein within the Tn complex, is a
key regulator of muscle contraction. Calcium binding to cTnC
triggers the biomechanical cascade of contraction events within
the sarcomere (Gordon et al., 2000). Calcium binding to cTnC
induces a conformational change within the Tn complex, thereby
displacing Tropomyosin (Tm) from actin filaments to expose
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myosin binding sites and increasing the probability of cross-
bridges cycling. In the resting state of the myofilaments when
Ca2+ is not bound to cTnC, cTn complex anchors Tm in a
“Blocked” position, thereby, sterically hindering access to sites
on the thin filament where Myosin S1 heads can bind to
actin to form XBs (Gordon et al., 2000). Upon Ca2+ binding
cTnC undergoes a conformational change, which exposes a
hydrophobic patch within cTnC and allows cTnC to bind to
the switch peptide subunit of cardiac Troponin I (cTnI). Once
the cTnC has bound to the cTnI switch peptide, cTn complex
releases the anchoring Tm, allowing the Tm molecule to slide
around the actin filament. Tm molecules overlap, which leads
to cooperative interactions between nearest-neighbor thick-thin
myofilament proteins that can be affected by the stiffness of the
Tmmolecule. Tm moves from the Blocked state to a Closed state
in which myosin binding sites are partially exposed, and then to
an Open state where myosin such that actin binding sites on the
thin filament are exposed, thus initiating XB cycling (Vibert et al.,
1997; Gordon et al., 2000; de Tombe et al., 2010).
Mutations in regulatory thin filament sarcomeric proteins Tn
and α-Tm have been associated with DCM (Table 1) (Figure 1).
A clinical study of idiopathic DCM patients found mutations
in the Tn complex in 7% of patients, with severe prognosis for
patients with mutations in cTnC (Chang and Potter, 2005; Lu
et al., 2013). cTnC D75Y/E59D missense mutation was detected
in an adult male who suffered sudden cardiac death as a result
of idiopathic DCM (Lim et al., 2008). D75Y and E59D are
point mutations located in the low affinity Ca2+ binding site
on cTnC near the N-terminus. Studies in skinned and intact
cardiomyocytes have reported a marked decrease in calcium
sensitivity, cell shortening and force production for the double
mutant (D75Y/E59D) and D75Y alone in spite of the fact
that the mutations do not influence the intracellular calcium
homeostasis (Lim et al., 2008; Dweck et al., 2010). However,
both D75Y and E59D are required to reduce the actomyosin
ATPase activity and maximal force in muscle fibers, indicating
that E59D enhances the effects of D75Y (Dweck et al., 2010).
In addition to D75Y and E59D, the G159D cTnC mutation
has been found in human DCM patients and has been shown
to impair cTnC-cTnI interaction and decrease Ca2+ binding
affinity (Mogensen et al., 2004; Biesiadecki et al., 2007; Robinson
et al., 2007; Baryshnikova et al., 2008). G159D cTnC mutant
exhibits reduced opening and closing rates of N-terminus of
cTnC post-calcium binding and dissociating respectively (Dong
et al., 2008). Additionally, G159D cTnC mutant abolishes the
accelerated closing rate of the N-terminus of cTnC triggered by
PKAmediated phosphorylation of cTnI (Dong et al., 2008). Four
rare clinical variates (Y5H, M103I, D145E, and I148V) of TnnC1
have been reported in association with DCM (Hershberger
et al., 2010), of which Y5H cTnC mutation was reported in
a pediatric patient with idiopathic DCM concomitant with a
mutation in Myosin (Rampersaud et al., 2011). Three of these
(Y5H, M103I, and I148V) showed decreased calcium sensitivity
of myofilaments and impaired response of the myofilament
to undergo Ca2+ desensitization upon PKA phosphorylation
(Pinto et al., 2011). The fourth variant D145E presented with
a MyBP-C rare variant. Given that D145E mutation shows
increased calcium sensitivity and is associated with HCM, it is
quite plausible that the concomitantly present MyBP-C mutation
mediated the observed DCM response (Landstrom et al., 2008;
Pinto et al., 2011). Additionally, cTnC mutant Q50R has been
identified in a DCM family with a member with the rare disease
of peripartum dilated cardiomyopathy (van Spaendonck-Zwarts
et al., 2010).
A DCM associated mutation in cTnI, A2V, was found
to hinder cTnC-cTnI interaction via mammalian two-hybrid
luciferase assay (Murphy et al., 2004). Two other cTnI mutants,
K36Q, and N185K, were reported in 2009 and found to decrease
calcium sensitivity of actin-myosin S1 ATPase, maximal ATPase
activity and reduce calcium binding affinity of cTnC (Carballo
et al., 2009; Lu et al., 2013). Two more cTnI mutants P16T
and D180G were reported recently (Murakami et al., 2010;
Rampersaud et al., 2011).
An earlier study employing two-hybrid assays to investigate
cTnT mutations R131W, R205L, and D270N, all of which
have been found in human DCM patients, impaired cTnC-
cTnI/cTnC-cTnT interaction (Mogensen et al., 2004). A
contractility study in rabbit muscle fibers reported that these
mutations and TnT R141W decrease Ca2+ sensitivity of force
generation, maximal ATPase activity and myofilament sliding
speed (Mirza et al., 2005). Additionally, Robinson et al. reported
a decrease in calcium sensitivity of these cTnT mutants as well
with the exception of cTnT mutation D270N. D270N cTnT
led to a decrease cooperativity of Ca2+ binding but not overall
Ca2+ affinity of cTn as measured by pCa50 in reconstituted thin
filaments (Robinson et al., 2007). The1K210 cTnT mutation has
been shown to decrease Ca2+ sensitivity of force generation and
hinder cTnT-cTnI interaction without affecting maximum force
generation (Morimoto et al., 2002; Mogensen et al., 2004; Du
et al., 2007; Robinson et al., 2007). There are conflicting reports
on the effect of 1K210 on cooperativity of force generation
(Venkatraman et al., 2003; Du et al., 2007; Robinson et al.,
2007). Four missense mutations, R134G, R151C, R159Q, and
R205W, in cTnT were identified in probands with familial DCM
(Hershberger et al., 2009), of which two (R134G, and R205W)
were also reported in pediatric patients with familial DCM
(Rampersaud et al., 2011). Functional analysis of these mutations
in reconstituted myocytes showed decreased calcium sensitivity
of force development (Hershberger et al., 2009). Additionally,
a HCM associated mutant E244D, was identified in a DCM
associated proband (Hershberger et al., 2009) and in a pediatric
patient with familial DCM (Rampersaud et al., 2011). Further, a
cTnT mutation R139H showed decreased calcium sensitivity and
was reported in late onset DCM in a 70 year old woman (Morales
et al., 2010). This is interesting as usually cTnT mutations are
associated with early onset and aggressive form of DCM. Lastly,
E96K cTnT mutation was reported in a 5 month patient with
idiopathic DCM (Rampersaud et al., 2011).
Tm mutations E40K and E54K were identified in a GWAS,
and when reconstituted in rabbit muscle fibers were found
to decrease Ca2+ sensitivity (Olson et al., 2001; Mirza et al.,
2005). Interestingly, the E40K mutation was found to decrease
myofilament sliding speed while the E54Kmutation had no effect
on sliding speed (Mirza et al., 2005). Both mutations caused
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TABLE 1 | DCM associated cTn and Tm mutants and their known molecular (M) effects, cellular (C) effects, and organ level (O) effects.
Protein Mutation Effects at Molecular (M), Cellular (C), and Organ (O) level
cTnC D75Y M: Decreased calcium binding affinity of TnC, decreased free energy of cTnC conformational change (hydrophobic patch opening) on calcium
binding (Dewan et al., 2016)
C: Decreased calcium sensitivity of myofilaments, decreased cell shortening, decreased force production (Lim et al., 2008; Dweck et al., 2010)
E59D M: Decreased calcium binding affinity of TnC, increased free energy of cTnC conformational change (hydrophobic patch opening) on calcium
binding (Dewan et al., 2016)
C: No apparent change in calcium sensitivity, no known changes relative to wildtype (Lim et al., 2008; Dweck et al., 2010)
E59D/D75Y C: Reduced maximum myofibrillar ATPase activity and decreased maximum force of contraction in skinned fibers (Dweck et al., 2010)
G159D M: Decreased calcium binding, reduced opening and closing rate sof cTnC N-terminus, increased free energy of cTnC conformational change
(hydrophobic patch opening) on calcium binding, Impaired cTnC-cTnT interaction, blunted cTnC-cTnI interaction effect based on PKA
phosphorylation, impaired anchoring of cTnC to cTnI (Mogensen et al., 2004; Robinson et al., 2007; Baryshnikova et al., 2008; Dong et al.,
2008; Dewan et al., 2016)
C: Decreased calcium sensitivity of myofilaments, decreased maximal ATPase activity and myofilament sliding speed, dissociation between
calcium sensitivity and PKA mediated beta adrenergic response to TnI phosphorylation (Mirza et al., 2005; Biesiadecki et al., 2007; Robinson
et al., 2007; Memo et al., 2013)
Y5H C: Decreased calcium sensitivity of myofilaments, dissociation between calcium sensitivity and PKA mediated beta adrenergic response to TnI
phosphorylation, diminished capacity to recover force in skinned fibers, impaired thin-filament activation in ATPase assays (Pinto et al., 2011)
M103I C: Decreased calcium sensitivity of myofilaments, complete dissociation between calcium sensitivity and PKA mediated beta adrenergic
response to TnI phosphorylation, diminished capacity to recover force in skinned fibers, impaired thin-filament activation in ATPase assays
(Pinto et al., 2011)
D145E C: Increased calcium sensitivity of myofilaments, previously associated with HCM, reported with rare mutation in MyBP-C (Pinto et al., 2011)
I148V C: Decreased calcium sensitivity of myofilaments, dissociation between calcium sensitivity and PKA mediated beta adrenergic response to TnI
phosphorylation, diminished capacity to recover force in skinned fibers, impaired thin-filament activation in ATPase assays (Pinto et al., 2011)
Q50R Known to occur in peripartum DCM (van Spaendonck-Zwarts et al., 2010)
cTnI A2V M: Impaired cTnC-cTnI interaction (Murphy et al., 2004)
K36Q M: Decreased calcium binding to cTnC, Mediate movement of N-terminus region of cTnI upon phosphorylation of S22/23 by PKA (Howarth
et al., 2007)
C: Decreased maximal ATPase activity, decreased calcium sensitivity of actin-myosin S1 ATPase, dissociation between calcium sensitivity and
PKA mediated beta adrenergic response to TnI phosphorylation (Carballo et al., 2009; Memo et al., 2013)
D180G Associated with a pediatric patient with familial DCM (Rampersaud et al., 2011)
N185K C: Decreased maximal ATPase activity, decreased calcium sensitivity of actin-myosin S1 ATPase (Carballo et al., 2009)
P16T Associated with DCM (Murakami et al., 2010)
cTnT E96K Associated with idiopathic DCM; reported in 5mo patient (Rampersaud et al., 2011)
R131W M: Enhanced cTnC-cTnI and impaired cTnC-cTnT interactions (Mogensen et al., 2004)
C: Decreased calcium sensitivity, decreased maximal ATPase activity and myofilament sliding speed (Mirza et al., 2005)
R134G C: Decreased calcium sensitivity of force development (Hershberger et al., 2009; Rampersaud et al., 2011)
R139H C: Decreased calcium sensitivity of force development; late onset DCM (Morales et al., 2010)
R141W M: Increased affinity of cTnT to Tm (Lu et al., 2003)
C: No change (Venkatraman et al., 2003)/Decreased calcium sensitivity of myofilaments, decreased maximal ATPase activity and myofilament
sliding speed, dissociation between calcium sensitivity and PKA mediated beta adrenergic response to TnI phosphorylation, increases in
diastolic and peak intracellular calcium (Mirza et al., 2005; Memo et al., 2013; Ramratnam et al., 2016)
O: Dose-dependent mutation effect, DCM phenotype, slower intrinsic rates in sinus rhythm, reduced peak heart rate in response to
isoproterenol (Ramratnam et al., 2016)
R151C C: Decreased calcium sensitivity of force development (Hershberger et al., 2009)
R159Q C: Decreased calcium sensitivity of force development (Hershberger et al., 2009)
A171S Gender dependent DCM, more severe effects in males (Stefanelli et al., 2004)
R173W C: Altered calcium regulation and lower contractility (Sun et al., 2012; Davis et al., 2016)
R205W C: Decreased calcium sensitivity of force development (Hershberger et al., 2009; Rampersaud et al., 2011)
R205L M: Impaired cTnC-cTnI and cTnC-cTnT interactions (Mogensen et al., 2004)
C: Decreased calcium sensitivity of myofilaments, decreased maximal ATPase activity and myofilament sliding speed (Mirza et al., 2005)
∆K210 M: Impaired cTnC-cTnI and cTnC-cTnT interactions (Mogensen et al., 2004)
C: Altered calcium sensitivity of myofilaments, decreased maximal ATPase activity and myofilament sliding speed (Morimoto et al., 2002;
Robinson et al., 2002, 2007; Venkatraman et al., 2003; Mirza et al., 2005; Du et al., 2007; Ahmad et al., 2008)
(Continued)
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TABLE 1 | Continued
Protein Mutation Effects at Molecular (M), Cellular (C), and Organ (O) level
O: Dose-dependent mutation effect, DCM phenotype (Ahmad et al., 2008)
K235R M: Impaired cTnC-cTnI and cTnC-cTnT interactions (Mogensen et al., 2004)
E244D Identified in DCM associated proband and pediatric patient with familial DCM; previously associated with HCM (Hershberger et al., 2009;
Rampersaud et al., 2011)
D270N M: Impaired cTnC-cTnI and cTnC-cTnT interactions (Mogensen et al., 2004)
C: Decreased calcium sensitivity of myofilaments, decreased maximal ATPase activity and myofilament sliding speed, decreased cooperativity
(Mirza et al., 2005; Robinson et al., 2007)
αTm E40K M: Destabilization of Tm Dimers, may alter Tm-actin interaction (Olson et al., 2001; Chang et al., 2014)
C: Decreased calcium sensitivity of myofilaments, decreased maximal ATPase activity and myofilament sliding speed, dissociation between
calcium sensitivity and PKA mediated beta adrenergic response to TnI phosphorylation (Mirza et al., 2005; Memo et al., 2013)
E54K M: Destabilization of Tm Dimers, increased stiffness and decreased curvature in Tm (Chang et al., 2014; Zheng et al., 2016)
C: Decreased calcium sensitivity of myofilaments, no effect on maximal ATPase activity or myofilament sliding speed, dissociation between
calcium sensitivity and PKA mediated beta adrenergic response to TnI phosphorylation (Mirza et al., 2005; Memo et al., 2013)
D230N C: Decreased calcium sensitivity of myofilaments, dissociation between calcium sensitivity and PKA mediated beta adrenergic response to TnI
phosphorylation (Lakdawala et al., 2010; Memo et al., 2013)
K15N Associated with pediatric patients with familial DCM (Rampersaud et al., 2011)
I92T Associated with pediatric patient with familial DCM (Rampersaud et al., 2011)
A277V Associated with pediatric patient with familial DCM (Rampersaud et al., 2011)
localized destabilization of the Tm dimers and affect interactions
with actin which would then directly affect ATPase activity
(Chang et al., 2014). In addition, D230N Tm mutation showed
decreased calcium sensitivity of myofilaments, and dissociation
between calcium sensitivity and PKA mediated beta adrenergic
response to TnI phosphorylation (Lakdawala et al., 2010; Memo
et al., 2013). Lastly, multiple Tmmutations (K15N, I92T, A277V)
have been reported in pediatric cases with idiopathic or familial
DCM (Rampersaud et al., 2011).
The above-mentioned familial mutations in the regulatory
proteins cTn and α-Tm, that have been identified in human
patients over the course of years, display some wide-ranging
molecular effects that mainly converge to few cellular
mechanisms such as altered calcium sensitivity and decreased
ATPase activity ultimately leading to depressed contractile
force observed in DCM. A recent innovative motility assay
study proposed that the varying experimental findings of
DCM-associated thin filament mutations in α-Tm and cTn can
be explained by a decoupling of Ca2+ sensitivity from cTnI
phosphorylation by PKA (Memo et al., 2013). This finding, along
with the wide variety of mutations in thin filament proteins that
have been connected to the development of DCM, underscores
the urgency of studying the complicated cascade of contraction
events as a whole in order to create a cohesive picture of
DCM causes and progression. Genetically engineered animal
models provide an opportunity to understand the sequelae of
molecular and cellular events as they translate to the whole
heart level. Notably, genetically engineered mice with sarcomeric
mutations 1K210 (Du et al., 2007; Ahmad et al., 2008) and
R141W (Ramratnam et al., 2016) in cTnT have been generated.
These studies showed a gene-dosage effect on the cardiac
phenotype and recapitulated the human phenotype. Despite the
key genotype-to-phenotype insights gleaned from animal model
studies, most experimental studies have so far been conducted in
reconstituted in vitro systems. Majority of experimental studies
have measured the effects of thin filament protein mutations
on cell-level function, but have not looked more closely into
molecular mechanisms or expression of dysfunction on the
whole heart level. Multi-scale computational modeling offers
a complementary set of tools that can help us understand the
spatial and temporal transition to clinical DCM.
INSIGHTS AND CHALLENGES FROM
MOLECULAR MODELING OF
REGULATORY THIN FILAMENT PROTEIN
MUTATIONS
Structural determination from x-ray crystallography and NMR
studies has helped provide key insights into molecular basis
of cTnC function (Li and Hwang, 2015). Previously published
experimental and theoretical studies have used these structural
data to probe rapid, nanosecond and microsecond timescale
conformational dynamics, by using Brownian Dynamics (BD)
and Molecular Dynamics (MD) simulations, that are correlated
with calcium binding (Kekenes-Huskey et al., 2012; Kalyva et al.,
2014). MD and BD simulations are useful in-silico approaches
that have been employed to understand the molecular basis
of altered structural and functional dynamics of regulatory
myofilament proteins such as cTnC in varied states. For example,
Varughese and Li investigated, withMD, changes in the structural
dynamics of cardiac Tn, including TnC, upon binding bepridil,
a known inotropic agent (Varguhese and Li, 2011; Lindert
et al., 2012b) combined long time-scale MD simulations and BD
simulations to understand the dynamics of wild-type TnC in its
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FIGURE 1 | DCM associated mutations shown in regulatory thin filament proteins cTn and Tm. DCM mutations for cTn are shown in the cartoon
representing primary amino acid sequence of cTnC, cTnI, and cTnT and in the cTnC crystal structure of the 52 kDa domain of human cTn (PDB ID—1J1E) in the
calcium saturated form (cTnC in blue, cTnI in red, cTnT in orange, calcium in green, mutations in pink). Residues 1–182 are missing in the crystal structure of
cTnT—the mutations in that region have been enclosed within an open box and point to a cartoon rendering of residues 1–182 of cTnT (faded orange ribbon structure
juxtaposing Tm). DCM mutations in Tm are shown in crystal structure for Tm (PDB ID—1C1G) (Tm in teal, mutations in pink).
calcium-free, calcium-bound, and TnI-bound states, as well as
V44Q (Lindert et al., 2012a).
Intra-molecular dynamic changes in cTn can cause alterations
in: (a) the calcium binding affinity of cTnC; (b) the rate
of calcium dissociation from cTnC; (c) the forward rate of
cTnC conformation transition; (d) the reverse rate of cTnC
conformation transition; and (e) the structure of cTnC such that
there are differences in charge within the exposed hydrophobic
patch (Dewan et al., 2016). Additionally, cTn mutations can
affect interactions between cTnC, cTnI, and cTnT as well
as downstream contractile proteins such as Tm and actin
(Mogensen et al., 2004; Robinson et al., 2007). A recent in silico
study (Dewan et al., 2016) employed MD and BD simulations
to postulate the decreased calcium binding affinity of cTnC and
the altered rate of hydrophobic patch opening within cTnC as
the molecular basis of the reported changes in calcium sensitivity
and force production in the D75Y cTnC DCM mutant. An MD
study on residues 70–110 of cTnT found that familial HCM -
linked mutations R92L and R92W, located near the Tm binding
domain, lead to increased hinge movement downstream on
the cTnT molecule as well as decreased helical stability (Ertz-
Berger et al., 2005). Importantly, the study found that divergent
phenotypes emerge in a live mouse model of these mutations,
which demonstrates a limitation to modeling isolated proteins
(Ertz-Berger et al., 2005).
MD simulations have the potential to uncover biophysical
effects of DCM associated mutations in cardiac Tm. Recent MD
studies have explored the properties of Tm in healthy cases as
well as patho-physiological cases, noting that Tm stiffness may
impact downstream contractility events greatly (Li et al., 2010a,b;
Loong et al., 2012; Lehman et al., 2015). A 2012 study usedMD to
study familial HCM associated Tmmutations D175N and E180G
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and found that both mutations lead to increased flexibility of
Tm and therefore, decreased persistence length of the molecule
(Li et al., 2012). Another MD study has also been performed on
HCM Tm mutations E62Q, A63V, K70T, V95A, D175N, E180G,
L185R, E192K in order to explore the effects of point mutations
on Tm flexibility and Tm-actin interactions (Zheng et al., 2016).
In the case of DCM, a time-independent electrostatic snapshot
of the DCM associated Tm mutation showed that E54K and
E40K mutations alter the surface charge of Tm, which may affect
Tm-actin interaction (Olson et al., 2001; Chang et al., 2014). A
time-dependent MD study was also performed on the E54K Tm
mutant in combination with 7 actin monomers and showed that
this mutation causes increased stiffness and decreased curvature
in the Tm molecule overall while stabilizing and destabilizing
the coiled coil structure in different regions of the molecule and
greatly weakening Tm-actin binding (Zheng et al., 2016). More
MD studies are needed in the area of Tm DCM mutations in
order to visualize effects of other mutations, such as E40K, that
may affect Tm-actin and Tm-cTn interactions.
In-silico investigation of sarcomere protein structure-function
dynamics by MD and BD simulations provides key insights
toward understanding molecular effects of genetic mutations
and post-translational modifications (Lindert et al., 2015; Dewan
et al., 2016). However, these structure-function dynamics can
change significantly when myofilament proteins interact with
one another in an integrated physiological system. It has been
reported that kinetic rates of a given state transition vary
in isolated molecular states and integrated myofilament states
(Davis and Tikunova, 2008). This was well demonstrated in
a previous study where the off-rates of calcium binding were
studied in depth from isolated cTnC molecule to a structurally
integrated myofilament preparation (Davis and Tikunova, 2008).
The whole cTn complex has been modeled using MD, both with
and without Ca2+ bound (Varughese et al., 2010; Jayasundar
et al., 2014). A 2014 study proved the value of modeling the
complex as a whole, because removing Ca2+ from the regulatory
binding pocket on cTnC affected cTnC hydrophobic patch
opening as well as the folding and flexibility of the cTnI switch
region (Jayasundar et al., 2014). Moving further up in scale, an
integrated MD study of a whole thin filament including cTn, 14
actin monomers, and two overlapping Tm molecules illustrates
the importance of modeling inter-protein interactions along
the thin filament (Manning et al., 2011). The MD simulation
performed was only 1 ns in length, but was able to accurately
capture the rotation of the I-T arm in the Tn complex as a direct
consequence of Ca2+ binding (Manning et al., 2011). The model
was used to study cTnT mutations R92W and R92L associated
with familial HCM and found that both mutations decrease
bending forces in the hinge region of cTnT which affects Tm
interaction, a downstream effect that may not have been captured
if the study were performed on isolated cTnT (Manning et al.,
2012).
Integration of molecular level state-transition kinetic data into
the sarcomere level is a key challenge yet to be solved for using in-
silico methods. At the molecular level it takes about 5–10 µs for
calcium to bind to cTnC (Lindert et al., 2012a,b). With the state-
of-the-art supercomputers we are now able to simulate molecular
events such as calcium-binding events and conformational state-
transitions within cTnC (a relatively small protein–18 kDa),
events that occur in the microseconds range. At the myofilament
level it takes about 700 ms for a contraction-relaxation cycle
to take place in a sarcomere (Kerckhoffs et al., 2010; Tøndel
et al., 2015). Recording the kinetics of all inter-molecular and
intra-molecular state transitions for every myofilament protein
during one contraction-relaxation cycle in a sarcomere is a
tremendous task, as illustrated by the 1 ns upper limit of an
MD simulation incorporating the full thin filament (Manning
et al., 2011). This is due to the enormous computational power
and speed that would be needed to solve for longer time
scale simulations and bulky proteins, such as Titin (3.9 MDa),
Myosin (220 kDa), and Tropomyosin (37 kDa), that form the
backbone of the sarcomeric thin and thick myofilament protein
complexes. Nevertheless, key insights into molecular behavior
of bulky proteins like Titin that are commonly known to
be mutated in DCM have been achieved by MD simulations
(Herman et al., 2012). An earlier MD study of Titin wherein,
single Ig domains of Titin were stretched reported sequential
unfolding of Ig domains corroborating experiments (Lu et al.,
1998, 2000; Gao et al., 2002). A recent study of Titin examined
the hydrophobic core region of the protein associated with a
DCM mutation V54M and reported destabilization of transition
from bend to coil in secondary structure of Titin and reduced
affinity to Z-disc protein T-cap/telethonin (Thirumal Kumar
et al., 2016). Given that Titin mutations are commonly associated
with DCM, molecular modeling of Titin domains associated with
DCM is mandated. While we have much to gain from MD
simulation studies, gaps in our experimental knowledge toward
understanding dynamics of molecular level interactions and
kinetics of state transitions between thick and thin myofilament
proteins compound the challenges in standardizing conditions
and validating results from the molecular simulation studies.
INSIGHTS AND CHALLENGES FROM
IN-SILICO TRANSLATION OF MOLECULAR
LEVEL CHANGES TO THIN FILAMENT
MECHANICS
The mathematical formulation of cardiac myofilament models
that explicitly incorporate spatio-temporal acto-myosin
interactions and stochastic XB formation to compute contractile
force have lagged behind electrophysiological models of the
heart (Rice and de Tombe, 2004; Zhang et al., 2016). This is
largely due to the (a) paucity of kinetic data on thick-thin
myofilament interactions and molecular state-transitions,
(b) requirement of partial-differential equations (PDEs) to
solve for explicit spatio-temporal acto-myosin interactions, (c)
lack of complete understanding of translation of steady-state
contractile force into a length and load-dependent dynamic
contractile force response via XB cycling, (d) difficulty in
solving for computationally expensive stochastic interactions,
(e) partial understanding of cooperative mechanisms involved
in myofilament activation, and (f) technical gaps in our
knowledge due to species differences and varied experimental
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conditions in scientific studies. Nonetheless, ordinary differential
equation (ODE) and Monte Carlo Markov models of regulated
co-operative myofilament activation with nearest neighbor
interactions, wherein some molecular states are lumped together
empirically and model parameters are optimized such that
the best-fit of the base model to the experimentally measured
steady-state force-calcium data-sets is achieved, have been
formulated (Noble, 2002; Rice et al., 2003, 2008; Puglisi et al.,
2004; Rice and de Tombe, 2004; Hussan et al., 2006; Campbell
et al., 2010; Aboelkassem et al., 2015; Sewanan et al., 2016). These
relatively simplified mean-field Markov models of cooperative
myofilament activation and contraction have helped provide
deeper insights as to how changes in inter-molecular and
intra-molecular interactions in myofilament proteins can alter
steady-state myofilament properties (myofilament calcium
sensitivity and cooperativity of myofilament activation) and
function (maximal force generation), which can then translate to
cardiac pump dysfunction as reported in DCM.
Arguably the most logical type of sarcomere-level model
to begin with, when testing the effects of point mutations on
thin filament proteins, is a Markov model of thin filament
activation. One such model, originally developed in 2010 and
since expanded for a variety of applications, consists of 26
spatially explicit regulatory units (RUs), each RU including
7 actin monomers, one Tm molecule, and cTn (Campbell
et al., 2010). The model captures cooperativity of thin filament
activation by relying on the Tm position (blocked, closed, or
open) of each RU’s nearest neighbor in order to determine rates
governing state transitions. Using this model as a starting point,
further studies have been able to test a variety of contractility
protein mutations at a larger spatial and temporal scale than MD
simulation can reasonably accomplish. A relevant example is a
recent study that simulated Tm mutations E180G and D175N,
which have been found in HCM patients, using a Monte Carlo
framework extension of the Campbell model (Sewanan et al.,
2016). MD simulations indicated that both Tmmutation increase
Tm flexibility while lowering persistence length of the molecule
(Li et al., 2012). The thin filament model was able to simulate
experimentally gathered wildtype and mutant contraction data
by altering Tm persistence length, transition rates between the
blocked and closed Tm states, and percentage of the XB cycle
spent in the attached force-producing state (Sewanan et al., 2016).
MD simulation data of isolated Tm can offer information on
persistence length but not on Tm-actin interaction or XB cycling,
which were discovered to be possible downstream effects of these
mutations.
A previously published multi-scale modeling study from our
group was one of the first studies to directly incorporate the
molecular changes computed from BD and MD simulations,
in the DCM mutant D75YcTnC, into a six-state Markov model
of steady-state myofilament contraction (Dewan et al., 2016)
(Figure 2). The key results from the study reported that the
intra-molecular changes (decreased calcium binding affinity
of cTnC and depressed rate of hydrophobic patch opening
during cTnC conformational change) in D75Y cTnC mutant
are sufficient to explain the observed decrease in myofilament
calcium sensitivity under steady-state experimental conditions in
skinned cardiomyocytes. Additionally, the study highlighted how
DCM mutants like E59D cTnC which appear to have healthy
myofilament response in skinned myofilament experiments,
can in fact be harboring molecular modifications which can
potentially turn deleterious under stressful conditions for the
myocardium. A weakness of this study was that they did not
model the effects of the double mutant D75Y/E59D. This would
have been more appropriate as both mutations, D75Y, and
E59D are needed for a reduction in maximum myofibrillar
ATPase and maximum force of contraction in skinned fibers.
Additionally, The D75Y mutant is important for the effect seen
in calcium binding affinity, however the “cellular” phenotype
may not be explained solely by a single mutation based on
the in vitro data. This study was instrumental in its scope, as
it bridged the genotypic defects at sarcomeric protein level
to myofilament phenotype in silico, by directly incorporating
molecular parameters from BD and MD simulations into
appropriate markov states of cTnC activation. The study
again displays the numerous challenges for the mathematical
modeler in scaling from molecular level to myofilament levels
to compute steady-state contractile force, as MD data was
insufficient to fully capture cellular mutant contractility changes
which may be due to cTnC-cTnI interaction or other protein
interactions in the sarcomere as shown in case of G159D cTnC
mutant. It is important to note that prediction of steady-state
force-calcium data is not predictive of cellular phenotype
by itself. For example, a reduction in calcium sensitivity of
myofilaments can be compensated for by an increase in calcium
transient. In such a case there will be no apparent change in
contractile function at the cellular level. Similarly, an increase
in calcium sensitivity of myofilaments can be offset by defects
in mechano-sensing. In fact these compensatory changes are
integral to the process of cardiac remodeling leading to DCM.
Further, as is evident in many DCM mutants (see Table 1),
change in calcium sensitivity is not the only predisposing
factor in DCM and the acto-myosin ATPase activity should
also be modeled in. Therefore, it is important to factor in
the contractile phenotype from an intact cell and incorporate
dynamic coupling in a model between thin-thick myofilaments,
passive tension, calcium homeostasis, and mechano-
transduction, at the least to be considered a cellular level
model.
Given the gaps in our knowledge of kinetic rates during
molecular transitions and variations in experimental data
collated from numerous studies, the mathematical modeler is
required to carefully choose explicit Markov states within an
appropriate framework, and to standardize technical variates
of species, temperature, and molecular state in order to glean
meaningful insights from any multi-scale computational study.
It is known that various rodent species (mouse, rat, guinea
pig) express variable isoforms of key myofilament proteins
under normal conditions, for e.g., mouse and rat express α-
myosin heavy chain (MHC) isoform (Rundell et al., 2005),
whereas, guinea pigs express β-MHC under basal conditions
(van der Velden et al., 1998). Given that α-MHC is at
least three times faster than β-MHC, this difference in basal
conditions in rodents is sufficient to alter the rate of XB
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FIGURE 2 | Schematic showing incorporation of molecular data of cTnC activation obtained from BD and MD simulations into a six-state Markov
model of myofilament activation at steady-state conditions, as an example of bridging molecular to cellular scales in a modeling study by Dewan
et al. (2016).
cycling significantly (Rundell et al., 2005). Isoform switches
in myofilament proteins are known to occur in patho-
physiological conditions as well (Nakao et al., 1997). Similar
changes in protein isoform expression and kinetics have been
reported for other myofilament proteins (de Tombe and Solaro,
2000). These changes impact the myofilament properties of
calcium sensitivity, cooperativity and maximal force output
significantly. Additionally, increased temperature is known to
have a significant effect on increasing calcium sensitivity of
myofilaments and increasing the maximal developed contractile
force under steady-state conditions in intact and skinned
ventricular tissue/cells from various species (Harrison and Bers,
1989, 1990; de Tombe and Stienen, 2007). This is likely due
to alterations in molecular kinetics of state transitions of
myofilament proteins with temperature. Also, kinetics of state-
transitions can vary significantly in isolated molecular states
vs. integrated systems, as elucidated in an earlier study where
the off-rates of calcium binding were studied in depth from
isolated cTnC molecule to a structurally integrated myofilament
preparation (Davis and Tikunova, 2008). These biophysical
variates must be accounted for during longitudinal scaling from
molecular states to myofilament states, as failing to do so
can potentially exaggerate or mask the magnitude of, and can
even potentially alter the direction of, steady-state myofilament
properties as reported for a mutation. It is imperative to note
that this is not always possible due to paucity of experimental
data, still, careful consideration must be given to these variates
in order to arrive at meaningful analysis from in-silico studies
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and to achieve good quantitative agreement with experimental
data.
INSIGHTS AND CHALLENGES WHILE
SCALING FROM THIN FILAMENT
MECHANICS TO THICK FILAMENT
MECHANICS
Results of Markov models of cooperative myofilament activation
with nearest neighbor interactions just described suggest that
a meaningful prediction toward patho-physiological outcome
of genetic mutations is possible in-silico (Dewan et al., 2016;
Sewanan et al., 2016). While this, of course, does not mean
that the models are entirely correct in their predictions, as the
whole system is not explicitly represented; it does suggest that
the key myofilament properties are adequately represented to
recapitulate fairly complex phenomena. These Markov models
adequately describe the process of thin filament activation,
such that the myofilament contractile response is mediated
by a prescribed length-clamp and/or calcium-clamp at any
given point of time. However, under physiological conditions,
myofilament activation and XB cycling are temporally modulated
by cyclical variation in length, calcium, and loading conditions
during a contraction-relaxation cycle (ter Keurs et al., 1988).
Modeling thick-thin myofilament effects into a dynamic model
of contraction, wherein length-dependence and load-dependence
of the myofilaments have been incorporated, will allow us to
further gain quantitative insights in the shortening response of
the contractile machinery and the work done by myofilaments.
This is imperative to scaling the effects of the identified DCM
mutant from genotype to phenotype.
The length-dependence of myofilament activation and the
load-dependence of the rate of myofilament shortening, are
tightly regulated and complex properties of the healthy
myocardium that are highly dependent on the spatio-temporal
arrangement of the myofilaments. In a simplistic view of
our understanding of cardiac biomechanics, length dependence
of myofilament activation is modulated by the degree of
overlap between thick and thin filaments and calcium sensitivity
of myofilaments (Huxley and Hanson, 1954; Huxley and
Niedergerke, 1954; Dobesh et al., 2002; de Tombe et al., 2010).
On the other hand, load-dependence of rate of myofilament
shortening is modulated by number of XBs in the strongly
bound state, distance between the thick and thin filaments,
myosin isoform, degree of thick-thin filament cooperativity, rate
of XB cycling, and stiffness of XBs (Edman, 1979; Hunter et al.,
1998; McDonald et al., 1998; Herron et al., 2001; Janssen et al.,
2002; Konhilas et al., 2002). Ultimately, the twitch dynamics
of the myofilaments are the key determinants of the cardiac
pump output during various phases of the cardiac cycle (Moss
and Buck, 2011). In reality, we are yet to fully comprehend
the molecular basis of these dynamic emergent myofilament
properties and their modulators. An explicit PDE model that
simulates the myofilament contraction-relaxation cycle while
recapitulating length-dependent myofilament activation and
force-velocity relationships is yet to be described to the best
of our knowledge. However, phenomenological models based
on empirical relationships have been described to quantitatively
recapitulate these myofilament properties (Hunter et al., 1998;
Lumens et al., 2009; Kerckhoffs et al., 2010). Phenomenological
vs. explicit Huxley-type muscle models of XB cycling have been
discussed before (Winters and Stark, 1987).
Computational models of XB cycling dynamics are key toward
scaling-up and integrating length dependence and dynamic
muscle activation into studies of thin filament DCM proteins.
For example, the Rice ODE model of XB cycling accurately
mimics length dependence of active/passive forces and Ca2+
binding, while simplifying a complex myofilament geometry by
keeping track of the overlap fraction between thick and thin
filaments (Rice et al., 2008). This model has been expanded in
more recent studies to include more complex geometries and
metabolic intermediates, and has been incorporated into organ-
scale finite element models through solving the sarcomere model
at different points in a finite element mesh (Gurev et al., 2010;
Tran et al., 2010; Sugiura et al., 2012; Washio et al., 2012).
Although, the model traditionally calculates force from a half
sarcomere and extrapolates to cell-level force values, it may be
possible to explicitly model a full cell with 32 sarcomeres using a
Blue Gene supercomputer in order to capture cooperativity of the
whole cell (Hussan et al., 2006). Another XB modeling approach
more explicitly models the sarcomere geometry by including
3 half thick filaments surrounded hexagonally by 13 half thin
filaments, mathematically modeled by a 3D spring array using
finite element analysis and governed by Monte Carlo processes
(Chase et al., 2004). This model importantly includes filament
compliance in its calculations, creating a more biophysically
accurate window into the individual proteins making up
the myofilament. The Chase model has been used to study
specific familial HCM-associated cTnI mutations by converting
experimentally gathered Ca2+ transient information into altered
probability of XB activation (Kataoka et al., 2007). However,
this study assumes that altered Ca2+ binding kinetics are the
sole contributor to altered contractility without considering the
interaction of mutated cTnI with other thin filament proteins.
When searching for XB models that will be able to accurately
model DCM sarcomere mutations, mechanistic models are more
promising as they allow for direct input of protein-level changes
into a larger scale model.
Phenomenological computational models of twitch tension,
which do not explicitly translate the molecular behavior of
myofilament proteins to the myofilament properties, can still
provide invaluable insight in the workings of the myocardium.
Therefore, it is critical to underscore the key considerations and
challenges to take into account when formulating dynamic
models of cardiac twitch. Temperature dependence of
myofilament dynamics, loading conditions (preload and
afterload), frequency of electrical pacing which determines
the calcium load, and biological species, are biophysical
experimental variates that significantly alter twitch dynamics
(Stull et al., 2002). Previous studies have reported frequency
and temperature dependent changes in contraction-relaxation
dynamics and maximal twitch force, based on phase-plane
analysis of dynamic force-calcium relationships from intact rat
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myocardium (Janssen et al., 2002). Briefly, increasing frequency
of stimulation resulted in a increased developed force, enhanced
myofilament responsiveness to calcium and abbreviated twitch
duration; increasing temperature from (22 to 37◦C), while
maintaining stimulation frequency and preload, resulted in
biphasic effects - between 22 and 30◦C, developed force did not
decrease despite abbreviated twitch duration; between 30 and
37◦C, a steep decline in developed twitch force was observed.
This would suggest independent temperature dependence on
myofilament activation and relaxation kinetics. An earlier study
elegantly measured the relationship between cardiac work output
and external load in single rat cardiomyocytes (Nishimura et al.,
2004). They reported work output of cardiomyocytes under a
range of loading conditions ranging from isometric, unloaded
and physiologically loaded conditions. Alterations in loading
conditions affect XB cycling rates and force-velocity relations.
Factoring in the effect of loading conditions, imposed on the
myocyte during experimental study from which parameters are
being collated, is crucial to correct interpretation of modeling
results and for scaling the results to the organ level. Lastly,
different experimental studies report data from different
biological species, each of which expresses different myofilament
protein isoforms that can independently alter twitch dynamics
(Clark et al., 1982; Tøndel et al., 2015). It is important that
careful consideration be given to these variables as models are
parameterized.
SUMMARY, PERSPECTIVES AND
CONCLUSIONS
This review is focused toward demonstrating the feasibility
and applicability of multi-scale modeling to gain mechanistic
insights into role of known genetic DCMmutations in contractile
proteins (Figure 3). We discuss some of the insights that can
be gained from computational models of cardiac biomechanics
when scaling from molecular states to cellular level states. We
have described the considerations and challenges that need to be
accounted for, when computationally modeling the mechanical
effects of sarcomeric mutations of DCM from genotype to
cellular phenotype. In particular, we discussed the difficulties in
standardizing parameters for a multi-scale modeling study from
varied experimental data sets. An important aspect that requires
careful consideration and work in modeling studies is coupling
FIGURE 3 | Schematic illustrating the scope of multi-scale modeling techniques, panning spatial and temporal scales, to complement experimental
data at all biological scales. Representative examples of modeling frameworks from molecular to cellular (solid black arrow—focus of this review) to whole heart
level (dotted black arrow) and growth modeling (dotted gray arrow) are shown.
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of calcium homeostasis and mechano-transduction mechanisms
to myofilament mechanics. Sarcomere generated force cannot
predict the organ level phenotype in entirety if upstream and
downstream regulatory mechanisms in the cell are not coupled
to it. In order to comprehensively translate to the cellular scale,
coupling of models of active tension to models of (a) passive
tension mediated by Titin, (b) upstream calcium homeostasis
mechanisms mediating CICR, (c) cytoskeletal proteins and z-
disc proteins that sense and transmit force signals, (d) ATP, ROS
and energy regulation by mitochondria, (e) insulin signaling, (f)
beta-adrenergic signaling pathways, and (g) signaling networks
mediating nuclear transcription response toward sarcomere
addition should be considered. However, with added complexity
in models the degree of ambiguity in results also increases
which may prove futile. It is important to note that DCM
is a disease characterized by an organ level phenotype, so in
order to understand the complex cascade that can cause a
point mutation in a contractile protein to lead to growth and
remodeling of the heart as a whole it is necessary to scale current
molecular and cellular level models to finite element models of
the heart with realistic geometries. For more information on
whole heart modeling and its potential, detailed reviews and
modeling frameworks exist (Campbell and McCulloch, 2011;
Trayanova, 2011; Sugiura et al., 2012; Zhang et al., 2016). Of
note is the recent study reporting phenomenological modeling of
the tension integral of the cardiomyocyte twitch as the predictor
for DCM and HCM phenotype in cardiomyopathies (Davis
et al., 2016). Furthermore, given that familial DCM manifests
clinically over-time it is pertinent to simulate pathological cardiac
remodeling leading to DCM. Growth modeling frameworks
utilizing stress or strain as the growth stimulus for sarcomere
addition at the whole-heart level coupled with cardiac mechanics
have been recently reviewed and present with a promising
avenue to scale-up (Göktepe et al., 2010; Kerckhoffs et al., 2012).
In addition, mechanistic frameworks for modeling biochemical
signaling networks that have previously been formulated (Zeigler
et al., 2016), such as for PKA mediated beta-adrenergic
signaling (Ryall et al., 2012), will be useful tools as cardiac
signaling in DCM is being studied based on RNAseq and
phosphoprotemics (Burke et al., 2016; Kuzmanov et al., 2016).
Formulating explicit models of molecular behavior and scaling
them longitudinally to cellular levels is an extremely challenging
task and perhaps not without its own pitfalls. Nonetheless,
in-silico modeling of cardiac biomechanics, in parallel with
the experimental studies, is a powerful set of tools that can
be applied toward integrative and quantitative understanding
of DCM.
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